Abivax positive long-term Ph. II data

Abivax announced excellent interim data on the long-term open-label extension phase of it’s Ph. IIb at a reduced 25mg dose od (versus 50mg od in Ph. IIb). In this extension study, patients who completed the 4-year Ph. IIa or 2-year Ph. IIb with 50mg obefazimod with clinical response could enter thi

Daily Healthcare - September 26, 2024

Abivax positive long-term Ph. II data

Abivax announced excellent interim data on the long-term open-label extension phase of it’s Ph. IIb at a reduced 25mg dose od (versus 50mg od in Ph. IIb). In this extension study, patients who completed the 4-year Ph. IIa or 2-year Ph. IIb with 50mg obefazimod with clinical response could enter thi

Tesco: H1 EBIT beat and a welcome FY EBIT guidance upgrade

Post Tesco's strong set of H1 figures (particularly EBIT while sales were just in line), we view the FY retail EBIT guidance upgrade to "around GBP2.9bn" as sufficient enough to please investors and prompt a few estimates upgrades among sell-side analysts. Tesco's exposure to the healthy UK market